Advertisement

Platelet Inhibitors

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu
Chapter

Abstract

The cutaneous adverse effects of aspirin (acetylsalicylic acid), dipyridamole, ticagrelor, cangrelor; thienopyridine derivatives such as ticlopidine, clopidogrel, and prasugrel; and platelet glycoprotein IIb/IIIa receptor antagonists such as abciximab, tirofiban, and eptifibatide are reviewed in this chapter. Aspirin is more commonly associated with cutaneous reactions due to its use as a nonsteroidal antiinflammatory drug.

Keywords

Platelet inhibitors Aspirin Acetylsalicylic acid Ticlopidine Clopidogrel Prasugrel Angioedema/urticaria Maculopapular Thrombotic thrombocytopenic purpura Lichenoid Lupus erythematosus Drug rash with eosinophilia and systemic symptoms Erythema multiforme/Stevens–Johnson syndrome/toxic epidermal necrolysis Fixed drug eruption 

References

  1. 1.
    Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292:3017–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol. 2003;28:123–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Yosipovitch G, Rechavia E, Feinmesser M, David M. Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol. 1999;41:473–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart. 2004;90:e14.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol. 2004;95:333.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheema AN, Mohammad A, Hong T, Jakubovic HR, Parmar GS, Sharieff W, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol. 2011;58:1445–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Báez-Montiel BB, Gutiérrez-Islas E, Herrera-Ontañón JR, Turabián JL. To enlighten and to dazzle: a case of an inadequate prescription of prasugrel with an adverse reaction of urticaria. Aten Primaria. 2013;45:64–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003;24:137–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Pharand C, Palisaitis DA, Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy. 2002;22:380–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Angelides S, Van der Wall H, Freedman SB. Acute reaction to dipyridamole during myocardial scintigraphy. N Engl J Med. 1999;340:394.PubMedCrossRefGoogle Scholar
  11. 11.
    Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, Suau R. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989;62:295–8.PubMedGoogle Scholar
  12. 12.
    Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother. 2006;40:1204–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang DC, Feldman DN, Kim LK, Minutello RM, Bergman G, Wong SC, Swaminathan RV. A strategy of ‘treating through’ a prasugrel-induced rash. Int J Cardiol. 2013;168:4381–2.PubMedCrossRefGoogle Scholar
  14. 14.
    Raccah BH, Shalit M, Danenberg HD. Allergic reaction to prasugrel and cross-reactivity with clopidogrel. Int J Cardiol. 2012;157:e48–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Nanau RM, Delzor F, Neuman MG. Efficacy and safety of Prasugrel in acute coronary syndrome patients. Clin Biochem. 2014;47:516–28. doi: 10.1016/j.clinbiochem.2014.03.005.PubMedCrossRefGoogle Scholar
  16. 16.
    Lokhandwala JO, Best PJ, Butterfield JH, Skelding KA, Scott T, Blankenship JC, et al. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv. 2009;2:348–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Owen P, Garner J, Hergott L, Page 2nd RL. Clopidogrel desensitization: case report and review of published protocols. Pharmacotherapy. 2008;28:259–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2012;9:441–6. doi: 10.7150/ijms.4549.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med. 1999;159:2524–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA. Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ. 2000;163:1463–4.Google Scholar
  21. 21.
    Briguori C, Manganelli F, Picardi M, Villari B, Ricciardelli B. Thrombocytopenia and purpura-like lesions associated with clopidogrel. Ital Heart J. 2001;2:935–7.PubMedGoogle Scholar
  22. 22.
    Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109:2203–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Graidis C, Golias C, Dimitriadis D, Dimitriadis G, Bitsis T, Dimitrelos I, et al. Eptifibatide-induced acute profound thrombocytopenia: a case report. BMC Res Notes. 2014;7:107.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:845–53.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Tsuda T, Okamoto Y, Sakaguchi R, Katayama N, Hara I, Hayashi H, Ota K. Purpura due to aspirin-induced platelet dysfunction aggravated by drinking alcohol. J Int Med Res. 2001;29:374–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Dogra S, Kanwar AJ. Clopidogrel bisulphate-induced photosensitive lichenoid eruption: first report. Br J Dermatol. 2003;148:609–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Kurokawa I, Umehara M, Nishijima S. Lichen planus-type drug eruption resulting from ticlopidine. Int J Dermatol. 2005;44:436–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Ruiz Villaverde R, Blasco Melguizo J, Mendoza Guil F, Martin Sanchez MC, Naranjo Sintes R. Generalized lichen planus-like eruption due to acetylsalicylic acid. J Eur Acad Dermatol Venereol. 2003;17:470–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Guijarro Guijarro B, Lopez Sanchez AF. Lichenoid reaction caused by clopidogrel, a new anti-platelet drug. Med Oral. 2003;8:33–7.PubMedGoogle Scholar
  32. 32.
    Braun-Moscovici Y, Schapira D, Balbir-Gurman A, Sevilia R, Nahir AM. Ticlopidine-induced lupus. J Clin Rheumatol. 2001;7:102–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Yokoyama T, Usui T, Kiyama K, Nakashima R, Yukawa N, Kawabata D, et al. Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Mod Rheumatol. 2010;20:405–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Spiera RF, Berman RS, Werner AJ, Spiera H. Ticlopidine-induced lupus: a report of 4 cases. Arch Intern Med. 2002;162:2240–3.PubMedCrossRefGoogle Scholar
  35. 35.
    Reich A, Bialynicki-Birula R, Szepietowski JC. Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol. 2006;45:1112–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc. 2005;80:1368–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Comert A, Akgun S, Civelek A, Kavala M, Sarigul S, Yildirim T, Arsan S. Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia. Int J Dermatol. 2005;44:882–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Ceylan C, Kirimli O, Akarsu M, Undar B, Güneri S. Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting. Am J Hematol. 1998;59:260.PubMedCrossRefGoogle Scholar
  39. 39.
    Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol. 2009;60:146–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Wolf I, Mouallem M, Rath S, Farfel Z. Clopidogrel-induced systemic inflammatory response syndrome. Mayo Clin Proc. 2003;78:618–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Ting HC, Adam BA. Stevens-Johnson syndrome. A review of 34 cases. Int J Dermatol. 1985;24:587–91.PubMedCrossRefGoogle Scholar
  42. 42.
    Strippoli D, Russo G, Simonetti V, Motolese A. Lyell syndrome due to ticlopidine. G Ital Dermatol Venereol. 2011;146:497–500.PubMedGoogle Scholar
  43. 43.
    Kaufman DW, Kelly JP. Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol. 2001;51:174–6.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Garcia CM, Carmena R, Garcia R, Berges P, Camacho E, Cotter MP, de la Hoz B. Fixed drug eruption from ticlopidine, with positive lesional patch test. Contact Dermatitis. 2001;44:40–1.PubMedCrossRefGoogle Scholar
  45. 45.
    Ghosh SK, Bandyopadhyay D. Clopidogrel-induced fixed drug eruption. J Eur Acad Dermatol Venereol. 2009;23:1202–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Chan HL. Fixed drug eruptions. A study of 20 occurrences in Singapore. Int J Dermatol. 1984;23:607–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Pintor E, Sanmartin M, Azcona L, Hernandez R, Fernandez-Cruz A, Macaya C. Leukocytoclastic vasculitis associated with ticlopidine. Rev Esp Cardiol. 2001;54:114–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Erpolat S, Nazli Y, Colak N, Yenidunya S. Leucocytoclastic vasculitis associated with clopidogrel. Cutan Ocul Toxicol. 2012;31:171–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Shetty RK, Madken M, Naha K, Vivek G. Leucocytoclastic vasculitis as a late complication of clopidogrel therapy. BMJ Case Rep. 2013;17:2013.Google Scholar
  50. 50.
    Ballmer-Weber BK, Widmer M, Burg G. Acetylsalicylic acid-induced generalized pustulosis. Schweiz Med Wochenschr. 1993;123:542–6.PubMedGoogle Scholar
  51. 51.
    Ellerbroek JC, Cleveland MG. Clopidogrel-associated acute generalized exanthematous pustulosis. Cutis. 2011;87:181–5.PubMedGoogle Scholar
  52. 52.
    Cannavo SP, Borgia F, Guarneri F, Vaccaro M. Acute generalized exanthematous pustulosis following use of ticlopidine. Br J Dermatol. 2000;142:577–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol. 2003;56:583.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Dakik HA, Salti I, Haidar R, Uthman IW. Drug points: ticlopidine associated with acute arthritis. BMJ. 2002;324:27.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Sugita K, Koga C, Yoshiki R, Izu K, Tokura Y. Papuloerythroderma caused by aspirin. Arch Dermatol. 2006;142:792–3.PubMedCrossRefGoogle Scholar
  56. 56.
    Salava A, Alanko K, Hyry H. Dipyridamole-induced eczematous drug eruption with positive patch test reaction. Contact Dermatitis. 2012;67:103–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Meissner M, Beier C, Wolter M, Kaufmann R, Gille J. Suberythrodermic pustular psoriasis induced by clopidogrel. Br J Dermatol. 2006;155:630–1.PubMedCrossRefGoogle Scholar
  58. 58.
    Mahajan VK, Khatri G, Prabha N, Abhinav C, Sharma V. Clopidogrel: a possible exacerbating factor for psoriasis. Indian J Pharmacol. 2014;46:123–4.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Wu S, Han J, Qureshi AA. Use of aspirin, nonsteroidal anti-inflammatory drugs, and aceta-minophen (paracetamol), and risk of psoriasis and psoriatic arthritis: A Cohort Study. Acta Derm Venereol. 2014. doi: 10.2340/00015555-1855.Google Scholar
  60. 60.
    Hsi DH, Mock DJ, Rocco Jr TA. Toxic erythroderma due to ticlopidine. N Engl J Med. 1999;340:1212.PubMedCrossRefGoogle Scholar
  61. 61.
    Durdu M, Baba M, Seçkin D. A case of bullous pemphigoid induced by aspirin. J Am Acad Dermatol. 2011;65:443–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Maron F. Mucosal burn resulting from chewable aspirin: report of case. J Am Dent Assoc. 1989;119:279–80.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations